ex-Founder and President, Living Pharma, Inc.
Ronald P. Dudek, is the Director of Technology Development and Marketing and Adapter CAR™ Program Manager at Lentigen Technology, Inc. (LTI). Ronald is the past President and co-founder of Living Pharma, Inc., a universal CAR T cell company founded in January 2015 and acquired by LTI June 29, 2017. He is also the Former Vice President of Commercial Strategy at Juno Therapeutics, Inc., and one of the first members of the company.
In 2011, Mr. Dudek was the Founding President of Restoration Oncology, Inc. (ROI), a CAR T cell company that developed anti-CD19 CAR T cells for the treatment of acute lymphoblastic leukemia and diffuse large B-cell lymphoma. The products, clinical program and intellectual property of ROI are now resident in Juno Therapeutics.
Mr. Dudek serves in executive roles at leading cell therapy companies including Xcyte Therapies, Inc., Aastrom Biosciences, Inc., and Miltenyi Biotec, Inc. He has 8 years of immunology research experience (Scripps Research Institute, Hybritech, Inc.), and 25 years of overall biotechnology business experience.